NRG-GY032
Trial Overview
Official Title
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)
Study Purpose
To determine if there are types of early-stage endometrial cancer that require less post-surgical treatment than the usual approach.
Diagnosis
Endometrial carcinoma which can be endometrioid, serous, clear cell, un/dedifferentiated, carcinosarcoma or mixed.Eligibility
Newly diagnosed, surgically resected, Stage I to III, no prior pelvic radiation
Intervention
Observation vs. Vaginal Brachytherapy vs. External Beam Radiation and/or Vaginal Brachytherapy depending on cancer stage and histiotype.
For more information, click the link below:
https://clinicaltrials.gov/study/NCT05640999?term=NRG-GY032&rank=1#study-overview
Key Participation Requirements
Trial Location(s)
Gender
Female
Age
18 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
NRG-GY032